Jana Portnow MD

Oncology•Duarte, CA

Hematologic Oncology, Neuro-Oncology

Physician

Join to View Full Profile

1500 Duarte RdDuarte, CA 91010
Phone+1 626-471-9200
Fax+1 626-301-8233

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1999 - 2002
Temple University HospitalResidency, Internal Medicine, 1994 - 1997
University of Rochester School of Medicine and DentistryClass of 1994

Certifications & Licensure

CA State Medical License 2002 - 2026
MD State Medical License 1998 - 2003
PA State Medical License 1995 - 1998
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2005 Jul 12
Completed
Phase 2
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Start of enrollment: 2005 Jan 01
Completed
Phase 1
Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors Start of enrollment: 2006 Jan 01
Completed
Phase 1
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma Start of enrollment: 2008 Apr 01
Completed
Phase 1
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Start of enrollment: 2008 Jun 01
Completed
Phase 1
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma Start of enrollment: 2010 Jul 01
Completed
Phase 1
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas Start of enrollment: 2010 Aug 01
Completed
Phase 1
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Start of enrollment: 2010 Dec 01
Completed
Phase 1
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2014 Feb 01
Terminated
Phase 2
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma Start of enrollment: 2014 Mar 01
Completed
Phase 2
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Start of enrollment: 2014 Oct 07
Completed
Phase 1
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Start of enrollment: 2016 Mar 07
ACTIVE_NOT_RECRUITING
PHASE1
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases Start of enrollment: 2018 Aug 31
ACTIVE_NOT_RECRUITING
PHASE1
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
ACTIVE_NOT_RECRUITING
NA
Roles: Contact
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors Start of enrollment: 2022 Apr 09
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas Start of enrollment: 2023 May 02
RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma Start of enrollment: 2024 Nov 15
WITHDRAWN
PHASE1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood-Brain Barrier Opening.
Karl J Habashy, Timothy W Synold, Ye Feng, Cristal Gomez, Christina Amidei
Clinical Cancer Research. 2025-08-14
3 citations
NCCN CNS Tumor Guidelines Update for 2024.
Louis Burt Nabors, Jona Hattangadi-Gluth, Craig Horbinski, Jana Portnow
Neuro-Oncology. 2025-03-07
Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial Teams.
Patrick A Cosgrove, Andrea H Bild, Thanh H Dellinger, Behnam Badie, Jana Portnow
Journal of Clinical Medicine. 2024-12-10

Press Mentions

Northwest Biotherapeutics: Data Is Done, Just Wait for ApprovalNovember 23rd, 2022
Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade GliomaAugust 2nd, 2022
City of Hope Scientist Receives $9.28 Million for CAR T Cell Immunotherapy Clinical Trial for Patients with HER2-Positive Breast Cancer That Has Spread to the BrainAugust 13th, 2019
Join now to see all

Grant Support

Pilot Feasibility Dose Escalation Study Using Intracerebral MicrodialysisNational Center For Research Resources2009
A Pharmacokinetic And Pharmacogenomic Study Of Patients With High-GradeNational Center For Research Resources2008–2009
A Phase I Study Of Bortezomib And Temozolomide In Patients With Refractory SolidNational Center For Research Resources2006–2009
A Pilot Feasibility Study Of Intracerebral Microdialysis To Determine The NeuroNational Center For Research Resources2007–2008